Preclinical Efficacy of Novel Dual PI3K/mTOR Inhibitor CMG002 As Potential Anti-Hepatocellular Carcinoma Agent

被引：0

作者：

Kim, Mi Na ^{[1
]}

Lee, Seung Min ^{[2
]}

Hwang, Seong-Gyu ^{[3
]}

机构：

[1] CHA Univ, CHA Bundang Med Ctr, Dept Internal Med, Pochon, South Korea

[2] CHA Univ, CHA Bundang Med Ctr, Inst Clin Res, Pochon, South Korea

[3] Cha Bundang Med Ctr, Seongnam, South Korea

来源：

HEPATOLOGY | 2018年 / 68卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

2233

引用

页码：1266A / 1266A

页数：1

共 50 条

[1] Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma
Mi Na Kim
Seung Min Lee
Jin Sung Kim
Seong Gyu Hwang
Cancer Chemotherapy and Pharmacology, 2019, 84 : 809 - 817
[2] Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma
Kim, Mi Na
Lee, Seung Min
Kim, Jin Sung
Hwang, Seong Gyu
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (04) : 809 - 817
[3] A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer
Choi, Hye Joung
Heo, Jin Hyung
Park, Ju Yeon
Jeong, Ju Yeon
Cho, Hyeon Ju
Park, Kyung Soon
Kim, Se Hwa
Moon, Yong Wha
Kim, Jin Sung
An, Hee Jung
GYNECOLOGIC ONCOLOGY, 2019, 153 (01) : 135 - 148
[4] Preclinical evaluation of novel PI3K/mTOR dual inhibitor SN202 as potential anti-renal cancer agent
Wang, Wan
Liao, Lidong
Wang, Yujun
Li, Hui
Suo, Zili
Long, Kai
Tang, Peixiao
CANCER BIOLOGY & THERAPY, 2018, 19 (11) : 1015 - 1022
[5] Anti-tumor Efficacy Profile of a Novel Dual PI3K/mTOR Inhibitor, DS-7423
Hirota, Y.
Sato, K.
Hama, Y.
Nagashima, Y.
Watanabe, R.
Suzuki, N.
Sugimura, M.
Shiose, Y.
EUROPEAN JOURNAL OF CANCER, 2012, 48 : 110 - 110
[6] A novel PI3K/mTOR dual inhibitor XH002 exhibited robust antitumor activity in NSCLC
Lv, Yuanhao
Du, Tingting
Ji, Ming
Wang, Chunyang
Lin, Songwen
Xue, Nina
Jin, Jing
Xu, Heng
Chen, Xiaoguang
JOURNAL OF DRUG TARGETING, 2019, 27 (04) : 451 - 459
[7] Preclinical Efficacy Of Rp6503, A Novel, Dual Pi3kδ/γ Inhibitor In Airway Disorders
Vakkalanka, S.
Routhu, K.
Govindarajulu, B.
Veeraraghavan, S.
Nagarathnam, D.
Viswanadha, S.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
[8] A preclinical study of a PI3K/mTOR dual inhibitor in the treatment of esophageal adenocarcinoma.
Omstead, Ashten N.
Zaidi, Ali Hussainy
Kosovec, Juliann E.
Matsui, Daisuke
Raj, Moses S.
Biederman, Robert W. W.
Finley, Gene Grant
Kelly, Ronan Joseph
Jobe, Blair A.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[9] PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy
Tarantelli, Chiara
Gaudio, Eugenio
Arribas, Alberto J.
Kwee, Ivo
Hillmann, Petra
Rinaldi, Andrea
Cascione, Luciano
Spriano, Filippo
Bernasconi, Elena
Guidetti, Francesca
Carrassa, Laura
Pittau, Roberta Bordone
Beaufils, Florent
Ritschard, Reto
Rageot, Denise
Sele, Alexander
Dossena, Barbara
Rossi, Francesca Maria
Zucchetto, Antonella
Taborelli, Monica
Gattei, Valter
Rossi, Davide
Stathis, Anastasios
Stussi, Georg
Broggini, Massimo
Wymann, Matthias P.
Wicki, Andreas
Zucca, Emanuele
Cmiljanovic, Vladimir
Fabbro, Doriano
Bertoni, Francesco
CLINICAL CANCER RESEARCH, 2018, 24 (01) : 120 - 129
[10] Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma
Koul, Dimpy
Wang, Shuzhen
Wu, Shaofang
Saito, Norihiko
Zheng, Siyuan
Gao, Feng
Kaul, Isha
Setoguchi, Masaki
Nakayama, Kiyoshi
Koyama, Kumiko
Shiose, Yoshinobu
Sulman, Erik P.
Hirota, Yasuhide
Yung, W. K. Alfred
ONCOTARGET, 2017, 8 (13) : 21741 - 21753

← 1 2 3 4 5 →